Pozsonyi Zoltán (1), Árokszállási Anita (2), Czuriga Dániel (3)
(1) Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest
(2) Debreceni Egyetem, Általános Orvostudományi Kar, Onkológiai Tanszék, Debrecen
(3) Debreceni Egyetem, Általános Orvostudományi Kar, Kardiológiai Intézet, Kardiológiai Tanszék, Debrecen

Despite continuously evolving cardiological and oncological treatments, cardiotoxicity emerging
in the course of anti-cancer therapy still poses a major problem today in the care of oncological patients.
While acutely presenting side effects might necessitate the modification, or, in a severe case, even the discontinuation of the treatment, late side effects may worsen long-term clinical outcomes. The primary aim of
the field of cardio-oncology is the cardiological monitoring of cancer patients to support successful treatment
completion and achieve a better clinical prognosis. The present work reviews the latest results concerning the
cardiotoxicity of anti-cancer treatments.

Kapcsolódó cikkek